Actuate Therapeutics, Inc. (ACTU) - Long-Term Debt to Capital

Actuate Therapeutics, Inc. (ACTU) operates from its own laboratory center in the US, while drug synthesis is delegated to external contractors to ensure supply stability. This price chart visualizes this process, where the indicator stands at 0.40. Business success relies on clinical trial recruitment rates and access to capital. The company's progressive image generates significant trust among physicians.

Diversifying the anti-tumor drug portfolio of Actuate Therapeutics, Inc. (ACTU) requires significant resources, making the management of long-term liabilities critical for business sustainability. This metric measures the proportion of borrowed funds with a maturity exceeding one year relative to equity, allowing for an assessment of financial leverage and the risk of creditor dependency. An optimal leverage balance ensures R&D development without compromising solvency, which is clearly reflected in the historical long-term debt-to-equity ratio.